Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influvac® 2007/2008 Immunogenicity and Reactogenicity Study
NCT00479921Phase 3Completed
- Sponsor
- Solvay
- Start
- Jun 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, open-label trial of subunit inactivated influenza vaccine in influenza (2 arms), sponsored by Solvay. Primary endpoints: Hemagglutination Inhibition titers at 3 weeks, Reactogenicity at 72 hours and 1 more. Started Jun 2007; status: completed.
02
Drugs
subunit inactivated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00479921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00479921.